Interactive Drug Benefit List
DIN/NPN/PIN 02298791 EMEND 80 MG ORAL CAPSULE APREPITANT
560000 GASTROINTESTINAL DRUGS
562200 ANTIEMETICS
562292 MISCELLANEOUS ANTIEMETICS
Date Listed/Coverage Update: 20-Jul-2010
Unit Price: 35.2538
LCA Price: N/A
MAC Price:

N/A

Unit of Issue: Capsule
Manufacturer: MERCK CANADA INC. (MFC)
ATC: A04AD12
1
Interchangeable Products: No

Coverage Status: RESTRICTED BENEFIT
Applies to Clients of: Non-Group Coverage (Group 1)
Coverage for Seniors (Group 66)
Palliative Coverage (Group 20514, Please note your client may have Group 1 or Group 66 coverage)
Child and Family Services (Group 20403)
Alberta Child Health Benefit (Group 20400)
Children and Youth Services (Group 19824)
Income Support (Group 19823)
Alberta Human Services (AISH) (Group 19823)
Alberta Adult Health Benefit (AAHB) (Group 23609)

Special Authorization Request Form:

N/A

RESTRICTED BENEFIT

This drug product must be prescribed by the Directors of Alberta Health Services - Cancer Care "Cancer Centres" (or their designates).

Review Status / Past Decisions

Indication Reviewing
Body
Submission
Completion
Date
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
CDR
Recommendation
Review
Status
N/A Expert Committee 2010/03/18 2010/07/20 Restricted Benefit
NAUSEA AND VOMITING (DUE TO CANCER CHEMOTHERAPY) Common Drug Review 2007/09/06 2008/10/01 Not a Benefit
NAUSEA AND VOMITING (DUE TO CANCER CHEMOTHERAPY) Common Drug Review 2007/09/06 2008/02/20 View CDR - List with criteria/condition
Indication N/A
Reviewing
Body
Expert Committee
Submission
Completion
Date
2010/03/18
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2010/07/20
CDR
Recommendation
Review
Status
Restricted Benefit
Indication NAUSEA AND VOMITING (DUE TO CANCER CHEMOTHERAPY)
Reviewing
Body
Common Drug Review
Submission
Completion
Date
2007/09/06
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2008/10/01
CDR
Recommendation
Review
Status
Not a Benefit
Indication NAUSEA AND VOMITING (DUE TO CANCER CHEMOTHERAPY)
Reviewing
Body
Common Drug Review
Submission
Completion
Date
2007/09/06
CDR
Recommendation
Date
2008/02/20
Expert Committee
Recommendation
Date
ADBL
Effective
Date
CDR
Recommendation
View
Review
Status
CDR - List with criteria/condition
To return to the printable Drug Benefit List and related publications, click here
Last Updated:
NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.
Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.
Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL), and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.